+ND Capital

nd.capital

VCMatch tracks +ND Capital as an investor focused on Biotech, Medtech, and Hardware companies and United States, Switzerland, and Europe markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Not specified

Focus Areas

Biotech, Medtech, Hardware

Geography

United States, Switzerland, and Europe

Investment Thesis

+ND Capital invests at the intersection of deep physical science and life science breakthroughs, targeting technologies that require substantial scientific expertise to commercialize. The firm was founded on the conviction that “significant breakthroughs would arise at the nanoscale and extensive expertise would be required to differentiate science from science fiction,” and has structured the team and approach around rigorous scientific assessment and long-term company building across Europe and the U.S.

Is +ND Capital right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

+ND Capital is most relevant for founders raising venture-backed rounds in Biotech, Medtech, Hardware, and Semiconductors, especially across United States, Switzerland, and Europe.

Focus statement

They focus on scientific/technology-driven companies in nanotechnology, physical sciences and life sciences, with a cross‑border orientation (Switzerland <> US) to access the best commercial opportunities. Team members are explicitly “focused on life sciences investments” and “focused on physical science investments.”

Value Add

Founding thesis rooted in nanotechnology and deep technical expertise: founder Aymeric Sallin’s research background at EPFL established a science-first approach.
High-caliber scientific leadership on the team (e.g., an Emeritus EPFL professor and Carl Pabo, a leading biophysicist and member of the US National Academy of Sciences), enabling rigorous technical due diligence.
Cross‑Atlantic sourcing and presence: founder “commuting between Switzerland and Boston/ Silicon Valley since 2007,” signaling an intentional bridge between European research and US commercialization opportunities.
Hands-on governance: multiple partners serve as board members or observers across portfolio companies, indicating active portfolio involvement.
Blend of scientific and commercial expertise: team includes experienced scientists, strategy consultants (Bain alumni), and finance/operations professionals, supporting both technical validation and business scaling.